November is Pulmonary Hypertension Awareness Month, and George Washington University Hospital’s Doctor Mardi Gomberg-Maitland ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung ...

Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

The company is effectively advancing its research, particularly with the anticipated Phase 3 PROSERA data expected in the fourth quarter of 2025 and the initiation of a Phase 3 trial for pulmonary ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...

Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

Another is producing a market-leading treatment for pulmonary arterial hypertension. But their appeal isn’t tethered to the ...

including I&I and pulmonary hypertension as well as others with the first approvals potentially coming in the next couple of years as well as many Phase 2 and Phase 3 data readouts and a significant ...

Results of Tenax Therapeutics' Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that IV ...